Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
Identifieur interne : 000117 ( PubMed/Curation ); précédent : 000116; suivant : 000118Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
Auteurs : Joaquim J. Ferreira [Portugal] ; Anne Rosser [Royaume-Uni] ; David Craufurd [Royaume-Uni] ; Ferdinando Squitieri [Italie] ; Nicholas Mallard [États-Unis] ; Bernhard Landwehrmeyer [Allemagne]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
Abstract
It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45.
DOI: 10.1002/mds.26308
PubMed: 26175332
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000117
Links to Exploration step
pubmed:26175332Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.</title>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.</nlm:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rosser, Anne" sort="Rosser, Anne" uniqKey="Rosser A" first="Anne" last="Rosser">Anne Rosser</name>
<affiliation wicri:level="1"><nlm:affiliation>Cardiff Schools of Medicine and Biosciences, Cardiff University, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cardiff Schools of Medicine and Biosciences, Cardiff University</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Craufurd, David" sort="Craufurd, David" uniqKey="Craufurd D" first="David" last="Craufurd">David Craufurd</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Squitieri, Ferdinando" sort="Squitieri, Ferdinando" uniqKey="Squitieri F" first="Ferdinando" last="Squitieri">Ferdinando Squitieri</name>
<affiliation wicri:level="1"><nlm:affiliation>IRCSS Neuromed, Pozzilli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCSS Neuromed, Pozzilli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mallard, Nicholas" sort="Mallard, Nicholas" uniqKey="Mallard N" first="Nicholas" last="Mallard">Nicholas Mallard</name>
<affiliation wicri:level="1"><nlm:affiliation>Amarin Pharma Inc., Bedminster, New Jersey, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amarin Pharma Inc., Bedminster, New Jersey</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Landwehrmeyer, Bernhard" sort="Landwehrmeyer, Bernhard" uniqKey="Landwehrmeyer B" first="Bernhard" last="Landwehrmeyer">Bernhard Landwehrmeyer</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitätsklinik Ulm, Ulm, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Universitätsklinik Ulm, Ulm</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26175332</idno>
<idno type="pmid">26175332</idno>
<idno type="doi">10.1002/mds.26308</idno>
<idno type="wicri:Area/PubMed/Corpus">000117</idno>
<idno type="wicri:Area/PubMed/Curation">000117</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.</title>
<author><name sortKey="Ferreira, Joaquim J" sort="Ferreira, Joaquim J" uniqKey="Ferreira J" first="Joaquim J" last="Ferreira">Joaquim J. Ferreira</name>
<affiliation wicri:level="1"><nlm:affiliation>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.</nlm:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rosser, Anne" sort="Rosser, Anne" uniqKey="Rosser A" first="Anne" last="Rosser">Anne Rosser</name>
<affiliation wicri:level="1"><nlm:affiliation>Cardiff Schools of Medicine and Biosciences, Cardiff University, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cardiff Schools of Medicine and Biosciences, Cardiff University</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Craufurd, David" sort="Craufurd, David" uniqKey="Craufurd D" first="David" last="Craufurd">David Craufurd</name>
<affiliation wicri:level="1"><nlm:affiliation>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Squitieri, Ferdinando" sort="Squitieri, Ferdinando" uniqKey="Squitieri F" first="Ferdinando" last="Squitieri">Ferdinando Squitieri</name>
<affiliation wicri:level="1"><nlm:affiliation>IRCSS Neuromed, Pozzilli, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>IRCSS Neuromed, Pozzilli</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Mallard, Nicholas" sort="Mallard, Nicholas" uniqKey="Mallard N" first="Nicholas" last="Mallard">Nicholas Mallard</name>
<affiliation wicri:level="1"><nlm:affiliation>Amarin Pharma Inc., Bedminster, New Jersey, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Amarin Pharma Inc., Bedminster, New Jersey</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Landwehrmeyer, Bernhard" sort="Landwehrmeyer, Bernhard" uniqKey="Landwehrmeyer B" first="Bernhard" last="Landwehrmeyer">Bernhard Landwehrmeyer</name>
<affiliation wicri:level="1"><nlm:affiliation>Universitätsklinik Ulm, Ulm, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Universitätsklinik Ulm, Ulm</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="In-Process"><PMID Version="1">26175332</PMID>
<DateCreated><Year>2015</Year>
<Month>09</Month>
<Day>03</Day>
</DateCreated>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>30</Volume>
<Issue>10</Issue>
<PubDate><Year>2015</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.</ArticleTitle>
<Pagination><MedlinePgn>1426-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26308</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">It has been suggested that treatment with ethyl-eicosapentaenoic acid (EPA) may improve motor function in patients with Huntington's disease (HD) with cytosine-adenine-guanine repeat numbers of <45.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This multicenter, randomized, double-blind, placebo-controlled 6-month trial compared the effects of ethyl-EPA versus placebo on 290 subjects with mild-to-moderate HD. The primary endpoint was the change from baseline to 6 months in the Total Motor Score 4 (TMS-4) component of the Unified Huntington's Disease Rating Scale (UHDRS). Secondary endpoints included change from baseline in UHDRS subscores and Clinical Global Impression (CGI).</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences in TMS-4 scores were noted between treatment groups. Similarly, there were no significant differences between groups on any of the UHDRS subscores or CGI scores.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Ethyl-EPA was not beneficial in patients with HD during 6 months of placebo-controlled evaluation.</AbstractText>
<CopyrightInformation>© 2015 International Parkinson and Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ferreira</LastName>
<ForeName>Joaquim J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rosser</LastName>
<ForeName>Anne</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Cardiff Schools of Medicine and Biosciences, Cardiff University, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Craufurd</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>University of Manchester, Manchester Academic Health Sciences Center and Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Squitieri</LastName>
<ForeName>Ferdinando</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>IRCSS Neuromed, Pozzilli, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mallard</LastName>
<ForeName>Nicholas</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Amarin Pharma Inc., Bedminster, New Jersey, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Landwehrmeyer</LastName>
<ForeName>Bernhard</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Universitätsklinik Ulm, Ulm, Germany.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2015</Year>
<Month>07</Month>
<Day>14</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Huntington's disease</Keyword>
<Keyword MajorTopicYN="N">clinical trial</Keyword>
<Keyword MajorTopicYN="N">eicosapentaenoic acid</Keyword>
<Keyword MajorTopicYN="N">ethyl-EPA</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year>
<Month>10</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2015</Year>
<Month>5</Month>
<Day>21</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2015</Year>
<Month>5</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="aheadofprint"><Year>2015</Year>
<Month>7</Month>
<Day>14</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2015</Year>
<Month>7</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2015</Year>
<Month>7</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>7</Month>
<Day>16</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">26175332</ArticleId>
<ArticleId IdType="doi">10.1002/mds.26308</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000117 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000117 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:26175332 |texte= Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26175332" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |